What Does the FDA Approval of Roflumilast Mean for Patients with Seborrheic Dermatitis?

In this interview, Neal Bhatia, MD, reacts to the FDA’s approval of roflumilast foam as well as the approval’s background and implications for patients with the inflammatory skin condition.

Related Keywords

United States , Americans , Neal Bhatia , Therapeutics Clinical Research , Drug Administration , Practical Dermatology , Fda , Approval , Seborrheic Dermatitis , Roflumilast , Foam ,